HYBRID EVENT: You can participate in person at Renaissance London Heathrow Hotel, United Kingdom or Virtually from your home or work.

Evgeny Pokushalov

 

Evgeny Pokushalov

Triangel Scientific,
United States of America

Abstract Title: Efficacy of AI-Guided Dietary Supplement Prescriptions Versus Traditional Methods for Lowering LDL Cholesterol: A Randomized Parallel-Group Pilot Study

Biography:

MD (Б-1 077979; University of Russia, 2002), PhD, Professor of Medicine. Present Appointment: since 2020 Deputy Director of the Center for New Medical Technologies 1997-1999 Residency of Cardiology, Research Institute of Cardiology, Tomsk 1999-2002 Post-graduate course of Cardiosurgery, Research Institute of Cardiology, Tomsk 2003 Hopital Haut-Leveque, Bordeaux-Pessac, France 2004 St Georg Hospital, Hamburg, Germany 2005 San Raffaele University Hospital, Milan, Italy 2012 Principles and Practice of Clinical Research, Harvard Medical School, USA

Research Interest:

Emerging evidence suggests that personalized dietary supplement regimens can significantly influence lipid metabolism and cardiovascular risk. The efficacy of AI-guided dietary supplement prescriptions, compared to standard physician-guided prescriptions, remains underexplored. In a randomized, parallel-group pilot study, 70 patients aged 40-75 years with LDL-C levels between 70-190 mg/dL were enrolled. Participants were randomized to receive either AI-guided dietary supplement prescriptions or standard physician-guided prescriptions for 90 days. The primary endpoint was the percent change in LDL-C levels. Secondary endpoints included changes in total cholesterol, HDL-C, triglycerides, and hsCRP. Supplement adherence and side effects were monitored. Sixty-seven participants completed the study. The AI-guided group experienced a 25.3% reduction in LDL-C levels (95% CI: -28.7% to -21.9%), significantly greater than the 15.2% reduction in the physician-guided group (95% CI: -18.5% to -11.9%; p<0.01). Total cholesterol decreased by 15.4% (95% CI: -19.1% to -11.7%) in the AI-guided group compared to 8.1% (95% CI: -11.5% to -4.7%) in the physician-guided group (p<0.05). Triglycerides were reduced by 22.1% (95% CI: -27.2% to -17.0%) in the AI-guided group versus 12.3% (95% CI: -16.7% to -7.9%) in the physician-guided group (p<0.01). HDL-C and hsCRP changes were not significantly different between groups. The AI-guided group received a broader variety of supplements, including plant sterols, omega-3 fatty acids, red yeast rice, coenzyme Q10, niacin, and fiber supplements. Side effects were minimal and comparable between groups. AI-guided dietary supplement prescriptions significantly reduce LDL-C and triglycerides more effectively than standard physician-guided prescriptions, highlighting the potential for AI-driven personalization in managing hypercholesterolemia.